This therapeutic modality targets key signaling pathways that are essential for tumor angiogenesis, specifically the vascular endothelial growth factor-vascular endothelial growth factor receptor (VEGF-VEGFR) pathway, in order to disrupt the formation of tumor blood vessels. This evidence concerns the gene KDR and neoplasm.